Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Pharmacogenetic Study of Bisoprolol Treatment in Patients With Uncontrolled Essential Hypertension (BRAVE)

NCT02398929 is registered in ClinicalTrials.gov with Chinese University of Hong Kong as lead sponsor.

NCT NCT02398929
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02398929 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Pharmacogenetic Study of Bisoprolol Treatment in Patients With Uncontrolled Essential Hypertension (BRAVE)
Lead sponsor
Chinese University of Hong Kong
Phase
Phase 4
Overall status
Completed
Start date
January 31, 2013
Completion date
January 5, 2021
Enrollment
100 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension